Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

verely affected HAE patients. It is also beneficial that this C1-inhibitor therapy is also to be approved for therapy of acute attacks and pre-procedure prevention."

"This positive CHMP opinion marks a key step in making Cinryze available to HAE patients across Europe and beyond that choose to proactively address their disease," commented Thierry Darcis, M.D., ViroPharma's vice president, general manager, Europe.  "We estimate that there are several thousand patients throughout Europe who suffer from this debilitating disease, and with this recommendation, these patients may soon benefit from the unique use of Cinryze to either prevent their attacks or treat them when they occur, with the added convenience of self administration after appropriate training.  ViroPharma is committed to providing important medicines to patients with unmet medical needs, and we look forward to working closely with physicians across Europe toward this important goal."

The CHMP is the scientific advisory body of the EMA responsible for reviewing Marketing Authorization Applications for medicinal products for human use.  The CHMP positive opinion forms the scientific basis for the European Commission to issue a binding decision for a Centralized Marketing Authorization, once issued, is valid throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. The anticipated timeframe for the European Commission decision is in the second quarter of 2011.  A summary of the CHMP opinion will be available here: http://tinyurl.com/2am4ubc.  Please select "C" to access the Cinryze summary opinion.

Continued Darcis, "Our work is already well underway towards preparing for our commercial launch in Europe, with the goal of making this important therapeutic product available to European patients as soon as possible."

Cinryze w
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. ... conducted in Melbourne, Australia ... the potential treatment of paroxysmal supraventricular tachycardia (PSVT).  ... MSP-2017 was well tolerated at single doses up ... safety profile, desirable PK properties including rapid onset, ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... Inc. (Nasdaq: EFJI ), a leading provider of secure ... ended September 30, 2009. Revenues were $24.4 million, gross ... $(0.06) per diluted share, for the three months ended September ... and contract awards, the third quarter revenue results were not ...
... A new treatment for autism appears to normalize ... MD, FAACAP, BCIA-EEG. , In addition to ... "u" EEG pattern reflecting impaired brain function, particularly in ... speech and bonding. , However, Quantitative ...
Cached Medicine Technology:EF Johnson Technologies Announces Third Quarter Results 2EF Johnson Technologies Announces Third Quarter Results 3EF Johnson Technologies Announces Third Quarter Results 4EF Johnson Technologies Announces Third Quarter Results 5EF Johnson Technologies Announces Third Quarter Results 6EF Johnson Technologies Announces Third Quarter Results 7EF Johnson Technologies Announces Third Quarter Results 8New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:11/24/2014)... York (PRWEB) November 24, 2014 Gersowitz Libo ... that it has received national Tier recognition in the 2015 ... Achieving a tiered ranking signals a unique combination of quality ... very proud to receive this honor and especially grateful to ... this important honor and ranking possible,” said Jeff S. Korek, ...
(Date:11/24/2014)... Pittsburgh, PA (PRWEB) November 24, 2014 ... as he was trying to cross the street in ... "The driver never saw him. I came up with ... easily visible at night." , He developed the Safety ... night or in low-lighting conditions. The device ensures that ...
(Date:11/23/2014)... November 24, 2014 iFitDress.com, a well-known wedding ... black evening gowns . They are now offered at ... offer will last from now to Dec. 15. The main ... , All the company’s high quality items are ideal options ... a large sum of money. All its new mint cocktail ...
(Date:11/23/2014)... The report, “Market Snapshot: Aesthetic Lasers ... Asia-Pacific” provides quantitative analysis of the three aesthetic ... body contouring devices, non-invasive body contouring devices and ... data by revenue and volume over the 2006 ... South Korea, Australia and India. It uses data ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank ... an 8 year warranty on its selected hot water tanks. ... due to the impending winter season, it was important for ... service that the company provides. As a result, Pro Ace ... and Bradford hot water tanks. , “Every installer who ...
Breaking Medicine News(10 mins):Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... School of Medicine have discovered that drinking just 500ml ... pressure. The study, published online today in the American ... the treatment of cardiovascular disease. , Lead by Professor ... Barts and The London School of Medicine, and Professor ...
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... workforce raises serious,concerns, WASHINGTON, Feb. 5 ... strong objections to President,Bush,s FY2009 budget for both ... the FY 2009 budget reflects some poor choices ... setting a hazardous course for,the future., "The ...
... a clue leading researchers at Washington University School of ... approach for Niemann-Pick disease, a rare, deadly neurodegenerative disorder. ... disease, the researchers suggest that chemical compounds could potentially ... machinery. And they believe the approach also could be ...
... ... Xactly Incent on-demand solution, SAN JOSE, Calif., ... performance management, today announced that Volcano,Corporation (Nasdaq: VOLC ... diagnosis and treatment of vascular and structural heart,diseases, has ...
... ATLANTA, Feb. 5 Ingenious Med, leaders in ... practice management,announces record sales, product deployments, partnerships, and ... 2007 sales increased by,81% over 2006. This increase ... a,dramatic increase in IM,s overall profitability., In ...
Cached Medicine News:Health News:Research shows a daily does of beetroot juice can beat high blood pressure 2Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Association of Academic Health Centers Faults Bush's FY 2009 Budget 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 2Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 3Health News:Ingenious Med Reports Record Sales and Client Expansions in 2007 2
... launched the first generation HPLC system for ... a new level of automation to HPLC ... diabetes testing in Japan. Now in the ... G7 offers advanced automation; stable HbA1c results ...
... complete hematology automation to maximize workflow efficiency ... provides the flexibility to meet your laboratory ... module, one Load module, and one Unload ... basic system will incorporate a minimum of ...
... The STart benchtop coagulation ... of electro-mechanical clot detection. This ... icteric or other optically dense ... offers programmable and preprogrammed assays ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
Medicine Products: